Pharmaceuticals

The Rise Of Regulatory Approvals: Key To Innovation In The Anti-Hypertensive Drugs Is Influencing The Intravenous Iron Drugs Market

April 30, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Will The Market Value Of The Intravenous Iron Drugs Market Grow Between 2026 And 2030?

The market size for intravenous iron drugs has seen rapid expansion over recent years. It is forecast to grow from $3.81 billion in 2025 to $4.22 billion in 2026, at a compound annual growth rate (CAGR) of 10.8%. This historical growth can be ascribed to the high prevalence of iron deficiency anemia, the limitations inherent in oral iron absorption, the adoption of hospital-based anemia management protocols, increased utilization in dialysis centers, and the proven clinical effectiveness of intravenous iron therapies.

The intravenous iron drugs market is projected for substantial expansion in the upcoming years, with its value anticipated to reach $6.34 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.7%. This expansion during the forecast period is primarily fueled by an increasing burden of chronic diseases, a growing demographic of dialysis patients, a rise in cancer-related anemia occurrences, the preference for swift hemoglobin correction, and the wider availability of outpatient infusion services. Prominent trends observed in this period include an intensified application in managing iron deficiency anemia, increased adoption among chronic kidney disease patients, a developing preference over oral iron therapies, the introduction and expansion of single-dose iron formulations, and higher utilization within oncology and gastroenterology.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23430&type=smp

What Primary Drivers Are Shaping The Intravenous Iron Drugs Market?

The increasing prevalence of chronic kidney disease (CKD) is anticipated to fuel the expansion of the intravenous iron drugs market in the foreseeable future. CKD is characterized by a gradual deterioration of kidney function over time, impeding the kidneys’ capacity to effectively filter waste and excess fluids from the blood. This rise in CKD cases is largely attributed to escalating rates of diabetes and hypertension, conditions known to cause progressive kidney damage. Intravenous iron drugs provide support to chronic kidney disease patients by replenishing iron stores, rectifying anemia, and elevating hemoglobin levels, which in turn enhances oxygen transport and lessens the dependence on erythropoiesis-stimulating agents. For instance, in July 2025, according to Hamadan University of Medical Sciences, a Iran-based university, the global number of newly diagnosed chronic kidney diseases is projected to rise to 25.06 million by 2030. Thus, the rising incidence of chronic kidney disease is a significant driver for the growth of the intravenous iron drugs market.

How Are Different Segments Classified In The Intravenous Iron Drugs Market Segment Analysis?

The intravenous iron drugs market covered in this report is segmented –

1) By Product Type: Iron Dextran, Iron Sucrose, Ferric Carboxymaltose, Other Product Types

2) By Indication: Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer, Other Diseases

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Iron Dextran: Low Molecular Weight Iron Dextran, High Molecular Weight Iron Dextran

2) By Iron Sucrose: Standard Iron Sucrose Injection, Iron Sucrose Complex

3) By Ferric Carboxymaltose: Single-Dose Ferric Carboxymaltose, Multiple-Dose Ferric Carboxymaltose

4) By Other Product Types: Ferumoxytol, Ferric Derisomaltose, Sodium Ferric Gluconate

Which Trends Are Impacting The Progress Of The Intravenous Iron Drugs Market?

Leading companies within the intravenous iron drugs market are concentrating on developing novel therapies, such as intravenous (IV) iron replacement therapy, to enhance efficacy, safety, and patient outcomes. Intravenous (IV) iron replacement therapy is a medical procedure that directly delivers iron into the bloodstream through an intravenous infusion. This treatment addresses iron deficiency and anemia, particularly in patients unable to tolerate or adequately absorb oral iron supplements. For instance, in June 2023, Daiichi Sankyo Company Limited, a Japan-based pharmaceutical company specializing in innovative drug development and healthcare solutions, announced that the U.S. Food and Drug Administration (FDA) had approved Injectafer (ferric carboxymaltose injection) for managing iron deficiency in adult patients with heart failure classified as New York Heart Association class II/III to boost exercise capacity. Injectafer is a widely used intravenous iron therapy, noted for rapidly replenishing iron levels in patients who cannot tolerate or do not respond well to oral iron supplements.

Who Are The Companies Driving Activity In The Intravenous Iron Drugs Market?

Major companies operating in the intravenous iron drugs market are Pharmacosmos A/S, American Regent Inc., Fresenius SE & Co. KGaA, Sandoz Group AG, Hikma Pharmaceuticals plc, Rockwell Medical Inc., Daiichi Sankyo Company Ltd., CSL Limited, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Zydus Lifesciences Limited, Vifor Pharma Management Ltd., Galenica Ltd., Aspen Pharmacare Holdings Limited, Lupin Limited, Aurobindo Pharma Limited, Jiangsu Hengrui Pharmaceutical Co. Ltd., Kissei Pharmaceutical Co. Ltd., Nanjing Hicin Pharmaceutical Co. Ltd

Get The Full Intravenous Iron Drugs Market Report:

https://www.thebusinessresearchcompany.com/report/intravenous-iron-drugs-global-market-report

Which Region Dominates The Intravenous Iron Drugs Market By Market Share?

North America was the largest region in the intravenous iron drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravenous iron drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Intravenous Iron Drugs Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/intravenous-iron-drugs-global-market-report

Browse Through More Reports Similar to the Global Intravenous Iron Drugs Market 2026, By The Business Research Company

Iron Deficiency Injectable Market Report 2026

https://www.thebusinessresearchcompany.com/report/iron-deficiency-injectable-global-market-report

Hemochromatosis Iron Overload Disease Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/hemochromatosis-iron-overload-disease-treatment-global-market-report

Intravenous Solutions Market Report 2026

https://www.thebusinessresearchcompany.com/report/intravenous-solutions-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795